---
title: "Boehringer Ingelheim (Germany): research papers"
description: "From 2017 to 2026 (so far), authors at Boehringer Ingelheim (Germany) took part in 26 papers in the tracked journals, most of them in health economics and policy (13), statistics (11) and AI (2). 2 of them were published in 2025, against 1 in 2017."
url: https://scholar4ai.com/companies/boehringer-ingelheim-germany
markdown_url: https://scholar4ai.com/companies/boehringer-ingelheim-germany.md
license: CC BY-NC 4.0 (https://creativecommons.org/licenses/by-nc/4.0/)
share_text: "From 2017 to 2026 (so far), authors at Boehringer Ingelheim (Germany) took part in 26 papers in the tracked journals, most of them in health economics and policy (13), statistics (11) and AI (2). 2 of them were… (as of 2026-11-05)"
data_url: https://scholar4ai.com/data/rankings.json
updated: 2026-11-05T06:02:37+09:00
window: 2026-10-07 to 2026-11-05
source: OpenAlex (CC0)
---

# Boehringer Ingelheim (Germany)

[Browse company research profiles](https://scholar4ai.com/companies/directory.md)

Papers in the tracked journals with an author at Boehringer Ingelheim (Germany): per year and category, where they are published, the institutions its researchers write with, and its most-cited papers. A paper counts as corporate when at least one of its authors is affiliated with an institution that OpenAlex classifies as a company; it counts once for each company among its authors' affiliations. Universities are the institutions OpenAlex classifies as education.

Back to the ranking: https://scholar4ai.com/rankings/companies.md

## Key findings

- From 2017 to 2026 (so far), authors at Boehringer Ingelheim (Germany) took part in 26 papers in the tracked journals, most of them in health economics and policy (13), statistics (11) and AI (2).
- 2 of them were published in 2025, against 1 in 2017.
- Since 2023, the institutions with the most of these papers were Merck & Co., Inc., Rahway, NJ, USA (United States) (5), Uppsala University (5) and Boehringer Ingelheim (United States) (4).
- The journals publishing most of them were BMC Medical Research Methodology (8), PharmacoEconomics - Open (3) and Patient (1).
- The most-cited of them is “Common pitfalls and recommendations for using machine learning to detect and prognosticate for COVID-19 using chest radiographs and CT scans” (Nature Machine Intelligence, 2021), with 1,045 citations.
- Since 2023, papers in the tracked journals cited 9 of its papers 45 times; 89% of those links came from papers with a university author and 0% from its own papers.
- Its own papers since 2023 cite archived papers 5 times, 60% of them papers with a company author.
- Across everything OpenAlex indexes, Boehringer Ingelheim (Germany) has 10,871 works with 1,241,176 citations (h-index 410).
- The tracked journals hold 21 of its 5,657 works in OpenAlex from 2017 to 2025 (0.4%).
- Its main research topics in OpenAlex are Chronic Obstructive Pulmonary Disease (COPD) Research (1,180), Diabetes Treatment and Management (1,068) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (900).

## Papers per year

*Papers per publication year and category*

| Category | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (so far) |
|---|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|
| [Health Economics and Policy](https://scholar4ai.com/categories/health-economics-and-policy.md) | 1 | 2 | 1 | 2 | 1 | 1 | 1 | 0 | 1 | 3 |
| [Statistics](https://scholar4ai.com/categories/statistics.md) | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 5 | 1 | 2 |
| [AI](https://scholar4ai.com/categories/ai.md) | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| All categories | 1 | 3 | 1 | 2 | 4 | 1 | 2 | 5 | 2 | 5 |

## Where the papers come from

*Journals with the most papers, since 2023*

| # | Journal | Papers |
|---:|---|---:|
| 1 | [BMC Medical Research Methodology](https://scholar4ai.com/journals/bmc-medical-research-methodology.md) | 8 |
| 2 | [PharmacoEconomics - Open](https://scholar4ai.com/journals/pharmacoeconomics-open.md) | 3 |
| 3 | [Patient](https://scholar4ai.com/journals/patient.md) | 1 |
| 4 | [Medical Image Analysis](https://scholar4ai.com/journals/medical-image-analysis.md) | 1 |
| 5 | [Health and Quality of Life Outcomes](https://scholar4ai.com/journals/health-and-quality-of-life-outcomes.md) | 1 |

*Institutions with the most papers, since 2023*

| # | Institution | Papers |
|---:|---|---:|
| 1 | [Merck & Co., Inc., Rahway, NJ, USA (United States)](https://scholar4ai.com/companies/merck-co-inc-rahway-nj-usa-united-states.md) | 5 |
| 2 | [Uppsala University](https://scholar4ai.com/institutions/uppsala-university.md) | 5 |
| 3 | Boehringer Ingelheim (United States) | 4 |
| 4 | Medical University of South Carolina | 4 |
| 5 | Amgen (United Kingdom) | 3 |
| 6 | [Lancaster University](https://scholar4ai.com/institutions/lancaster-university.md) | 2 |
| 7 | MRC Biostatistics Unit | 2 |
| 8 | [RWTH Aachen University](https://scholar4ai.com/institutions/rwth-aachen-university.md) | 2 |
| 9 | Rensselaer Polytechnic Institute | 2 |

*Countries with the most papers, since 2023*

| # | Country | Papers |
|---:|---|---:|
| 1 | Germany | 14 |
| 2 | United Kingdom | 10 |
| 3 | United States | 9 |
| 4 | Sweden | 5 |
| 5 | France | 1 |
| 6 | Netherlands | 1 |

*Keywords with the most papers, since 2023*

| # | Keyword | Papers |
|---:|---|---:|
| 1 | randomization | 3 |
| 2 | [cost-effectiveness](https://scholar4ai.com/keywords/cost-effectiveness.md) | 2 |
| 3 | obesity | 2 |
| 4 | platform trials | 2 |
| 5 | treatment imbalance | 2 |
| 6 | EMPEROR-Preserved trial | 1 |
| 7 | EQ-5D-5L | 1 |
| 8 | French health system | 1 |
| 9 | Markov model | 1 |
| 10 | SGLT2 inhibitors | 1 |

## Most-cited papers

*Most-cited papers since 2017*

| # | Citations | Per month | Title | Journal | Published | Authors |
|---:|---:|---:|---|---|---|---|
| 1 | 1,045 | 15.4 | [Common pitfalls and recommendations for using machine learning to detect and prognosticate for COVID-19 using chest radiographs and CT scans](https://doi.org/10.1038/s42256-021-00307-0) | [Nature Machine Intelligence](https://scholar4ai.com/journals/nature-machine-intelligence.md) | 2021-03-15 | Michael Roberts, Derek Driggs, Matthew Thorpe et al. |
| 2 | 109 | 1.0 | [The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review](https://doi.org/10.1007/s40273-018-0631-8) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 2018-02-28 | Alexander Diamantopoulos, Emily Wright, Katerina Vlahopoulou et al. |
| 3 | 27 | 0.8 | [Learning image representations for anomaly detection: Application to discovery of histological alterations in drug development](https://doi.org/10.1016/j.media.2023.103067) | [Medical Image Analysis](https://scholar4ai.com/journals/medical-image-analysis.md) | 2023-12-21 | Igor Zingman, Birgit Stierstorfer, Charlotte Lempp et al. |
| 4 | 26 | 0.4 | [Statistical inference for state occupation and transition probabilities in non-Markov multi-state models subject to both random left-truncation and right-censoring](https://doi.org/10.1016/j.ecosta.2021.09.008) | [Econometrics and Statistics](https://scholar4ai.com/journals/econometrics-and-statistics.md) | 2021-10-22 | Alexandra Nießl, Arthur Allignol, Jan Beyersmann et al. |
| 5 | 23 | 0.3 | [Incorporating the Environmental Impact into a Budget Impact Analysis: The Example of Adopting RESPIMAT® Re-usable Inhaler](https://doi.org/10.1007/s40258-019-00540-0) | [Applied Health Economics and Health Policy](https://scholar4ai.com/journals/applied-health-economics-and-health-policy.md) | 2019-12-06 | Gustaf Ortsäter, Fredrik Borgström, Mike Baldwin et al. |
| 6 | 21 | 0.4 | [A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction](https://doi.org/10.1007/s10198-022-01555-6) | [The European Journal of Health Economics](https://scholar4ai.com/journals/the-european-journal-of-health-economics.md) | 2022-12-04 | Ali Tafazzoli, Odette S. Reifsnider, Leana Bellanca et al. |
| 7 | 13 | 0.2 | [Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China](https://doi.org/10.1186/s12962-021-00299-z) | [Cost Effectiveness and Resource Allocation](https://scholar4ai.com/journals/cost-effectiveness-and-resource-allocation.md) | 2021-08-04 | Mafalda Ramos, Peng Men, Xu Wang et al. |
| 8 | 12 | 0.4 | [Selecting a randomization method for a multi-center clinical trial with stochastic recruitment considerations](https://doi.org/10.1186/s12874-023-02131-z) | [BMC Medical Research Methodology](https://scholar4ai.com/journals/bmc-medical-research-methodology.md) | 2024-02-28 | Oleksandr Sverdlov, Yevgen V. Ryeznik, Vladimir V. Anisimov et al. |
| 9 | 10 | 0.1 | [Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations](https://doi.org/10.1007/s10198-020-01186-9) | [The European Journal of Health Economics](https://scholar4ai.com/journals/the-european-journal-of-health-economics.md) | 2020-04-23 | Lotte Westerink, Jelmer Lennart Jens Nicolai, Carl Haakon Samuelsen et al. |
| 10 | 7 | 0.4 | [Seven Actions Towards Advancing Patient Authorship and Collaboration in Peer-Reviewed Publications](https://doi.org/10.1007/s40271-025-00750-w) | [Patient](https://scholar4ai.com/journals/patient.md) | 2025-07-02 | Trishna Bharadia, Jan Geißler, Rosie Robson et al. |

## Who cites its research

*Institutions whose papers cite it most, since 2023*

| # | Institution | Kind | Country | Links |
|---:|---|---|---|---:|
| 1 | [University of Cambridge](https://scholar4ai.com/institutions/university-of-cambridge.md) | University | United Kingdom | 5 |
| 2 | [Centre National de la Recherche Scientifique](https://scholar4ai.com/institutions/centre-national-de-la-recherche-scientifique.md) | Government | France | 4 |
| 3 | The Alan Turing Institute | Research facility | United Kingdom | 4 |
| 4 | Inserm | Government | France | 3 |
| 5 | University of Bremen | University | Germany | 3 |
| 6 | [Imperial College London](https://scholar4ai.com/institutions/imperial-college-london.md) | University | United Kingdom | 3 |
| 7 | Henan University of Chinese Medicine | University | China | 2 |
| 8 | [University of California, Los Angeles](https://scholar4ai.com/institutions/university-of-california-los-angeles.md) | University | United States | 2 |
| 9 | École des Hautes Études en Santé Publique | University | France | 2 |
| 10 | Université de Bourgogne | University | France | 2 |

## What its papers cite

*Institutions its papers cite most, since 2023*

| # | Institution | Kind | Country | Links |
|---:|---|---|---|---:|
| 1 | Novo Nordisk (Denmark) | Company | Denmark | 2 |
| 2 | [Health Economics and Outcomes Research (United Kingdom)](https://scholar4ai.com/companies/health-economics-and-outcomes-research-united-kingdom.md) | Company | United Kingdom | 2 |
| 3 | École Supérieure des Sciences Économiques et Commerciales | Other | France | 1 |
| 4 | Amgen (United States) | Company | United States | 1 |
| 5 | Pontificia Universidad Católica de Chile | University | Chile | 1 |
| 6 | William & Mary | University | United States | 1 |
| 7 | [King's College London](https://scholar4ai.com/institutions/king-s-college-london.md) | University | United Kingdom | 1 |
| 8 | [University of Bristol](https://scholar4ai.com/institutions/university-of-bristol.md) | University | United Kingdom | 1 |
| 9 | EuroQol Research Foundation | Nonprofit | Netherlands | 1 |
| 10 | Swedish Institute for Health Economics | Research facility | Sweden | 1 |

More: https://scholar4ai.com/corporate-citations.md · https://scholar4ai.com/industry-university.md

## In OpenAlex

*Boehringer Ingelheim (Germany) in OpenAlex*

| Item | Value |
|---|---|
| Type | Company |
| Location | Ingelheim, Rheinland-Pfalz, Germany |
| Units listed in OpenAlex | 27 |
| Works in OpenAlex | 10,871 |
| Citations | 1,241,176 |
| h-index | 410 |
| i10-index | 12,631 |
| 2-year mean citedness | 6.80 |
| Website | [www.boehringer-ingelheim.com/de](https://www.boehringer-ingelheim.com/de/) |
| ROR | [ror.org/00q32j219](https://ror.org/00q32j219) |
| OpenAlex | [openalex.org/I1330995197](https://openalex.org/I1330995197) |

*Works and citations per year in OpenAlex, and its papers in the tracked journals*

| Year | Works in OpenAlex | Citations received | In the tracked journals | Share |
|---|---:|---:|---:|---:|
| 2026 (so far) | 597 | 33,060 | 5 | 0.8% |
| 2025 | 693 | 37,805 | 2 | 0.3% |
| 2024 | 749 | 37,789 | 5 | 0.7% |
| 2023 | 647 | 33,914 | 2 | 0.3% |
| 2022 | 644 | 32,510 | 1 | 0.2% |
| 2021 | 665 | 32,832 | 4 | 0.6% |
| 2020 | 627 | 29,416 | 2 | 0.3% |
| 2019 | 660 | 23,935 | 1 | 0.2% |
| 2018 | 530 | 21,818 | 3 | 0.6% |
| 2017 | 442 | 20,018 | 1 | 0.2% |

*Main research topics (OpenAlex, all works)*

| # | Topic | Field | Works |
|---:|---|---|---:|
| 1 | Chronic Obstructive Pulmonary Disease (COPD) Research | Medicine | 1,180 |
| 2 | Diabetes Treatment and Management | Medicine | 1,068 |
| 3 | Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis | Medicine | 900 |
| 4 | Asthma and respiratory diseases | Medicine | 825 |
| 5 | Inhalation and Respiratory Drug Delivery | Medicine | 637 |

From OpenAlex's own record of the institution (CC0), read again monthly. Works and citations count everything OpenAlex indexes, not only the tracked journals; topics are OpenAlex's classification of those works.

## Cite this page

Scholar4AI. (2026). Boehringer Ingelheim (Germany). Journal and Conference Research Rankings. Retrieved November 5, 2026, from https://scholar4ai.com/companies/boehringer-ingelheim-germany

```bibtex
@misc{scholar4ai-companies-boehringer-ingelheim-germany,
  author = {{Scholar4AI}},
  title = {Boehringer Ingelheim (Germany)},
  year = {2026},
  howpublished = {\url{https://scholar4ai.com/companies/boehringer-ingelheim-germany}},
  urldate = {2026-11-05},
  note = {Journal and Conference Research Rankings; data from OpenAlex (CC0); licensed CC BY-NC 4.0}
}
```

License: CC BY-NC 4.0 (https://creativecommons.org/licenses/by-nc/4.0/).